TY - JOUR
T1 - Catheter Ablation versus Standard Conventional Treatment in Patients with Left Ventricular Dysfunction and Atrial Fibrillation (CASTLE-AF) - Study Design
AU - Marrouche, Nassir F.
AU - Brachmann, Johannes
AU - AUTHOR GROUP
AU - Andresen, D.
AU - Boersma, L.
AU - de Roy, L.
AU - Jordaens, L.
AU - Kautzner, J.
AU - Schunkert, H.
AU - Sporton, S.
AU - Siebels, J.
AU - Jürgen Vogt, J.
AU - Zrenner, B.
PY - 2009
Y1 - 2009
N2 - Methods: The catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial fibrillation trial (CASTLE-AF) is a randomized evaluation of ablative treatment of atrial fibrillation in patients with left ventricular dysfunction. The primary endpoint is the composite of all-cause mortality or worsening of heart failure requiring unplanned hospitalization using a time to first event analysis. Secondary endpoints are all-cause mortality, cardiovascular mortality, cerebrovascular accidents, worsening of heart failure requiring unplanned hospitalization, unplanned hospitalization due to cardiovascular reason, all-cause hospitalization, quality of life, number of therapies (shock and antitachycardia pacing) delivered by the implantable cardioverter-defibrillator (ICD), time to first ICD therapy, number of device-detected ventricular tachycardia and ventricular fibrillation episodes, AF burden, AF free interval, left ventricular function, exercise tolerance, and percentage of right ventricular pacing. CASTLE-AF will randomize 420 patients for a minimum of 3 years at 48 sites in the United States, Europe, Australia, and South America. (PACE 2009; 32:987-994)
AB - Methods: The catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial fibrillation trial (CASTLE-AF) is a randomized evaluation of ablative treatment of atrial fibrillation in patients with left ventricular dysfunction. The primary endpoint is the composite of all-cause mortality or worsening of heart failure requiring unplanned hospitalization using a time to first event analysis. Secondary endpoints are all-cause mortality, cardiovascular mortality, cerebrovascular accidents, worsening of heart failure requiring unplanned hospitalization, unplanned hospitalization due to cardiovascular reason, all-cause hospitalization, quality of life, number of therapies (shock and antitachycardia pacing) delivered by the implantable cardioverter-defibrillator (ICD), time to first ICD therapy, number of device-detected ventricular tachycardia and ventricular fibrillation episodes, AF burden, AF free interval, left ventricular function, exercise tolerance, and percentage of right ventricular pacing. CASTLE-AF will randomize 420 patients for a minimum of 3 years at 48 sites in the United States, Europe, Australia, and South America. (PACE 2009; 32:987-994)
U2 - https://doi.org/10.1111/j.1540-8159.2009.02428.x
DO - https://doi.org/10.1111/j.1540-8159.2009.02428.x
M3 - Article
C2 - 19659616
SN - 0147-8389
VL - 32
SP - 987
EP - 994
JO - Pacing and clinical electrophysiology
JF - Pacing and clinical electrophysiology
IS - 8
ER -